WOCKPHARMA - Swing Trade Analysis with AI Signals

Last Updated Time : 20 Dec 25, 07:02 am

Swing Trade Rating: 3.4

📊 WOCKPHARMA shows weak fundamentals with very high P/E (163 vs industry 30.6), low ROCE (4.40%), and negative ROE (-0.53%). Debt-to-equity at 0.76 is relatively high, adding financial risk. Technically, the stock is trading near both 50 DMA (1,368 ₹) and 200 DMA (1,393 ₹), suggesting consolidation. RSI at 54.2 is neutral, leaving room for upside. While quarterly PAT improved significantly (+250% YoY), sequential decline from 69 Cr. to 54 Cr. raises caution. This makes WOCKPHARMA a speculative swing trade candidate.

✅ Optimal Entry Price: 1,360–1,380 ₹ (near DMA support)

🚪 Exit Strategy (if already holding): Consider exit near 1,500–1,520 ₹ (resistance zone), or if RSI rises above 65.

Positive

• 📈 Quarterly PAT growth (+250%) highlights strong year-on-year recovery.
• 💹 EPS at 8.68 ₹ reflects earnings stability despite weak margins.
• 📊 Price near DMA 50 & DMA 200 provides technical support zone.
• 📉 Strong trading volume (5.53L vs avg 4.71L) supports liquidity for swing trades.

Limitation

• ⚠️ High P/E (163) vs industry average (30.6) indicates severe overvaluation.
• 📉 Negative ROE (-0.53%) and low ROCE (4.40%) highlight poor efficiency.
• 📊 High PEG ratio (6.73) signals expensive growth relative to earnings.
• 📉 Debt-to-equity (0.76) is higher than ideal, adding financial risk.

Company Negative News

• 📉 FII holding decreased (-0.19%), showing reduced foreign investor confidence.
• 📉 Sequential PAT decline from 69 Cr. to 54 Cr. raises earnings concerns.

Company Positive News

• 📈 Quarterly PAT growth (+250%) highlights operational improvement.
• 📊 Stable DII holding indicates neutral domestic institutional stance.

Industry

• 🏭 Industry P/E at 30.6 is much lower, suggesting peers may be more attractively valued.
• 📊 Pharma sector outlook remains positive, driven by global demand and regulatory approvals.

Conclusion

⚖️ WOCKPHARMA is a speculative swing trade candidate. Oversold fundamentals and high valuations limit upside, but technical support near DMA levels and strong YoY PAT growth provide tactical opportunity. Entry near 1,360–1,380 ₹ offers margin of safety, while exit near 1,500–1,520 ₹ is prudent. Strict stop-loss discipline is essential due to volatility and weak efficiency metrics.

Would you like me to extend this into a peer benchmarking overlay so you can compare WOCKPHARMA against other pharma peers like Sun Pharma, Cipla, and Dr. Reddy’s for relative strength and valuation positioning?